Considering the experience with immune therapy in MM, trametinib was discontinued, and ipilimumab (2 mg/kg, every three weeks), a CTLA-4 inhibitor, initiated, the latter being reported to be effective in combination with nivolumab in metastasized MM [23]. The gene discussed is CTLA4; the disease is Miyoshi myopathy.